Chemocentryx, Inc.

Anita Melikian

Solomon Ungashe

Cheng Hu

Sreenivas Punna

Andrew M K Pennell

Trevor T Charvat

Aaron Robert Novack

William L Thomas

Edward J Sullivan

Yibin Zeng

Penglie Zhang

Jay Patrick Powers

John Jessen Wright

Xuefei Tan

Andrew Mk Pennell

Aaron Novack

Yandong Li

Zheng Wei

Andrew Pennell

Jeff Jin

William D Thomas

Thomas J Schall

Antoni Krasinski

Brian E McMaster

John J Kim Wright

J J Wright

Jennifer M Burns

Andrew MK Pennell

Brian E Mcmaster

John J Wright

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Aryl sulfonamides

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Triazolyl phenyl benzenesulfonamides

Triazolyl pyridyl benzenesulfonamides

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides

Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

Inhibitors of human tumor-expressed CCXCKR2

Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.

Substituted quinolones and methods of use

Substituted benzamide compounds are provided along with methods for the use of those compounds for treating cancer. 

Substituted arylamides

Growing community of inventors

San Francisco, CA, United States of America

Anita Melikian